In addition, in an in vivo setting birabresib induced synthetic lethality via restoring loss of MYC repression in SMAD4-deficient CRC cells, confirming the data from McCleland and colleagues about the feasibility of treating MYC-overexpressing tumors with BET-i. Here, SMAD4 is linked to colorectal carcinoma.